CL2016001400A1 - Profármacos de amidas de piridona útiles como moduladores de canales de sodio. - Google Patents

Profármacos de amidas de piridona útiles como moduladores de canales de sodio.

Info

Publication number
CL2016001400A1
CL2016001400A1 CL2016001400A CL2016001400A CL2016001400A1 CL 2016001400 A1 CL2016001400 A1 CL 2016001400A1 CL 2016001400 A CL2016001400 A CL 2016001400A CL 2016001400 A CL2016001400 A CL 2016001400A CL 2016001400 A1 CL2016001400 A1 CL 2016001400A1
Authority
CL
Chile
Prior art keywords
sodium channel
prodrugs
channel modulators
amides useful
pyridone amides
Prior art date
Application number
CL2016001400A
Other languages
English (en)
Inventor
Sara Sabina Hadida-Ruah
Corey Anderson
Julian Marian Charles Golec
Beili Zhang
Benjamin Joseph Littler
Ali Keshavarz-Shokri
Tim Edward Alcacio
Daniel T Belmont
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of CL2016001400A1 publication Critical patent/CL2016001400A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • C07D213/18—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Abstract

COMPUESTOS DERIVADOS DE [2-FENOXI-4-BENZAMIDO-2-OXOPIRIDIN-1(2H) -IL]METILO, MODULADORES DE CANALES DE SODIO; COMPOSICION FARMACEUTICA; FORMA AMORFA; FORMA CRISTALINA; PROCEDIMIENTO PARA PREPARAR LA FORMA CRISTALINA; METODO PARA INHIBIR UN CANAL DE SODIO DEPENDIENTE DE VOLTAJE; METODO PARA TRATAR O DISMINUIR EL DOLOR.
CL2016001400A 2013-12-13 2016-06-08 Profármacos de amidas de piridona útiles como moduladores de canales de sodio. CL2016001400A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361915937P 2013-12-13 2013-12-13

Publications (1)

Publication Number Publication Date
CL2016001400A1 true CL2016001400A1 (es) 2016-12-16

Family

ID=52293220

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001400A CL2016001400A1 (es) 2013-12-13 2016-06-08 Profármacos de amidas de piridona útiles como moduladores de canales de sodio.

Country Status (32)

Country Link
US (6) US9163042B2 (es)
EP (2) EP3459958A1 (es)
JP (3) JP6463580B2 (es)
KR (1) KR102435145B1 (es)
CN (2) CN108395452B (es)
AP (1) AP2016009287A0 (es)
AU (2) AU2014362255B2 (es)
BR (1) BR122020007729B1 (es)
CA (1) CA2931550C (es)
CL (1) CL2016001400A1 (es)
CY (1) CY1121030T1 (es)
DK (1) DK3080134T3 (es)
EC (1) ECSP16025201A (es)
ES (1) ES2688590T3 (es)
GE (2) GEP20207082B (es)
HR (1) HRP20181563T1 (es)
IL (1) IL246061B (es)
LT (1) LT3080134T (es)
MX (2) MX2016007258A (es)
NZ (2) NZ760006A (es)
PE (1) PE20161131A1 (es)
PH (1) PH12016501028A1 (es)
PL (1) PL3080134T3 (es)
PT (1) PT3080134T (es)
RS (1) RS57700B1 (es)
RU (1) RU2692766C1 (es)
SG (2) SG11201604477SA (es)
SI (1) SI3080134T1 (es)
TW (3) TWI668226B (es)
UA (1) UA121379C2 (es)
WO (1) WO2015089361A1 (es)
ZA (1) ZA201603546B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2846787B1 (en) 2012-05-08 2018-08-29 Aeromics, Inc. Compounds for use in the treatment of aquaporin-mediated diseases
AU2014212426B8 (en) 2013-01-31 2018-05-10 Vertex Pharmaceuticals Incorporated Quinoline and Quinoxaline Amides as Modulators of Sodium Channels
NZ750187A (en) 2013-01-31 2020-09-25 Vertex Pharma Pyridone amides as modulators of sodium channels
KR102215620B1 (ko) 2013-07-19 2021-02-16 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 설폰아미드
RU2691951C2 (ru) 2013-11-06 2019-06-19 Аэромикс, Инк. Новые составы
EP3459958A1 (en) * 2013-12-13 2019-03-27 Vertex Pharmaceuticals Incorporated Process and intermediates for preparing prodrugs of pyridone amides useful as modulators of sodium channels
US11221329B2 (en) 2015-10-30 2022-01-11 Lieber Institute, Inc. Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity
WO2017147147A1 (en) * 2016-02-23 2017-08-31 PixarBio Corporation Compositions comprising nav1.7 selective inhibitors for treating acute, post-operative, or chronic pain and methods of using the same
AU2017261828B2 (en) * 2016-05-13 2023-04-13 Aeromics, Inc. Crystals
US11358977B2 (en) * 2017-05-16 2022-06-14 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
PE20201164A1 (es) 2017-07-11 2020-10-28 Vertex Pharma Carboxamidas como moduladores de los canales de sodio
US10495175B2 (en) * 2017-08-08 2019-12-03 Ford Global Technologies, Llc Composite materials having embedded metal ropes for increased damping capacity and methods of manufacturing same
AU2019218387A1 (en) * 2018-02-12 2020-08-27 Vertex Pharmaceuticals Incorporated A method of treating pain
CR20210209A (es) 2018-11-02 2021-05-20 Merck Sharp & Dohme 2-amino-n-heteroaril-nicotinamidas como inhibidores de
US20230062053A1 (en) 2019-01-10 2023-03-02 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US20220110923A1 (en) 2019-01-10 2022-04-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
TW202043200A (zh) * 2019-01-25 2020-12-01 大陸商江蘇恆瑞醫藥股份有限公司 ２－側氧基－１，２－二氫吡啶類衍生物、其製備方法及其在醫藥上的應用
WO2020169042A1 (zh) * 2019-02-20 2020-08-27 江苏恒瑞医药股份有限公司 6-氧代-1,6-二氢哒嗪类前药衍生物、其制备方法及其在医药上的应用
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020206119A1 (en) 2019-04-02 2020-10-08 Vertex Pharmaceuticals Incorporated Process for making pyridone amides and prodrugs thereof useful as modulators of sodium channels
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
WO2021018165A1 (zh) * 2019-07-30 2021-02-04 江苏恒瑞医药股份有限公司 吡啶苯甲酰胺类衍生物、其制备方法及其在医药上的应用
WO2021032074A1 (zh) * 2019-08-19 2021-02-25 江苏恒瑞医药股份有限公司 苯甲酰胺稠芳环类衍生物、其制备方法及其在医药上的应用
CA3150400A1 (en) * 2019-09-12 2021-03-18 Shanghai Jemincare Pharmaceuticals Co., Ltd PYRIDINE OXYNITRIDE, METHOD FOR PREPARATION AND USE
IL293592A (en) 2019-12-06 2022-08-01 Vertex Pharma Transduced tetrahydrofurans as sodium channel modulators
CA3182633A1 (en) 2020-06-17 2021-12-23 Ashok Arasappan 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
CN113880771B (zh) * 2020-07-03 2023-09-19 福建盛迪医药有限公司 一种选择性Nav抑制剂的结晶形式及其制备方法
US20230293556A1 (en) * 2020-08-05 2023-09-21 Jiangsu Simcere Pharmaceutical Co., Ltd. Pharmaceutical composition of aquaporin inhibitor and preparation method thereof
TW202214259A (zh) * 2020-08-19 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 一種選擇性ＮａＶ抑制劑的前藥及其晶型
CN111808019B (zh) * 2020-09-08 2020-11-27 上海济煜医药科技有限公司 一种并环化合物及其应用
CN114031518B (zh) 2020-12-08 2023-08-18 成都海博为药业有限公司 一种苄胺或苄醇衍生物及其用途
CN116710463A (zh) * 2020-12-18 2023-09-05 葛兰素史密斯克莱知识产权发展有限公司 用于抑制nav1.8电压门控钠通道和治疗nav1.8介导的疾病的化学化合物
TW202302118A (zh) * 2021-02-26 2023-01-16 大陸商江蘇恒瑞醫藥股份有限公司 一種選擇性ｎａｖ抑制劑的可藥用鹽、結晶形式及其製備方法
KR20240005878A (ko) 2021-05-07 2024-01-12 머크 샤프 앤드 돔 엘엘씨 Nav1.8 억제제로서의 시클로알킬 3-옥소피페라진 카르복스아미드 및 시클로헤테로알킬 3-옥소피페라진 카르복스아미드
CN117794919A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺类似物作为钠通道调节剂
BR112023025264A2 (pt) 2021-06-04 2024-02-20 Vertex Pharma Formas farmacêuticas sólidas e regimes posológicos compreendendo (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino ]piridina-2-carboxamida
EP4347583A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
CA3221960A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
AR126073A1 (es) 2021-06-04 2023-09-06 Vertex Pharma N-(hidroxialquil(hetero)aril)tetrahidrofuran carboxamidas como moduladores de canales de sodio
CN117813302A (zh) 2021-06-04 2024-04-02 沃泰克斯药物股份有限公司 经取代的四氢呋喃-2-甲酰胺作为钠通道调节剂
AR126669A1 (es) 2021-08-02 2023-11-01 Eurofarma Laboratorios S A COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
AR126670A1 (es) 2021-08-02 2023-11-01 Eurofarma Laboratorios S A COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
CN114288289A (zh) * 2022-02-17 2022-04-08 昆山彭济凯丰生物科技有限公司 具有镇痛和/或止痒功能的药物组合物及其应用
WO2023160509A1 (zh) * 2022-02-25 2023-08-31 中国科学院上海药物研究所 脒类衍生化合物及其制备方法和用途
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205778A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20230373925A1 (en) 2022-04-22 2023-11-23 Vertex Pharma Heteroaryl compounds for the treatment of pain
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
TW202348229A (zh) * 2022-06-02 2023-12-16 大陸商上海濟煜醫藥科技有限公司 吡啶氮氧化合物的製備方法
WO2023238064A1 (en) * 2022-06-09 2023-12-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
WO2024067783A1 (zh) * 2022-09-28 2024-04-04 上海济煜医药科技有限公司 含磷类化合物及其制备方法和医药应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02245793A (ja) 1989-03-20 1990-10-01 Hitachi Ltd マトリックス表示装置
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
EP1757932B1 (en) 2000-07-10 2010-09-08 Vertex Pharmaceuticals (San Diego) LLC Ion channel assay methods
JP2003034671A (ja) 2001-05-17 2003-02-07 Nippon Nohyaku Co Ltd ベンズアミド誘導体及び農園芸用薬剤並びにその使用方法
AP1822A (en) 2002-02-14 2008-01-30 Pharmacia Corp Substituted pyridinones as modulators of P38 MAP kinase.
WO2005013914A2 (en) * 2003-08-08 2005-02-17 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
CA2574600C (en) 2004-07-23 2010-08-31 Pfizer Inc. Pyridine derivatives
CN101466665B (zh) 2006-04-11 2013-12-04 沃泰克斯药物股份有限公司 适用作电压-门控钠通道抑制剂的组合物
EP2073806B1 (en) 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
ES2398606T3 (es) 2007-05-03 2013-03-20 Pfizer Limited Derivados de 2-piridin-carboxamida como moduladores de los canales de sodio
CA2701766A1 (en) * 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Amides useful as inhibitors of voltage-gated sodium channels
AU2008310660A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
RU2010118467A (ru) * 2007-10-11 2011-11-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ариламиды, пригодные в качестве ингибиторов потенциалзависимых натриевых каналов
KR20110033291A (ko) * 2008-07-23 2011-03-30 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물
AU2009309869A1 (en) * 2008-10-29 2010-05-06 F. Hoffmann-La Roche Ag Novel phenyl amide or pyridil amide derivatives and their use as GPBAR1 agonists
EP2382202A1 (en) 2008-12-23 2011-11-02 F. Hoffmann-La Roche AG Dihydropyridone amides as p2x7 modulators
WO2010074193A1 (ja) 2008-12-26 2010-07-01 大日本住友製薬株式会社 新規２環性複素環化合物
JP5685203B2 (ja) 2009-05-29 2015-03-18 ラクオリア創薬株式会社 カルシウムチャネル遮断薬またはナトリウムチャネル遮断薬としてのアリール置換カルボキサミド誘導体
AR077033A1 (es) 2009-06-11 2011-07-27 Hoffmann La Roche Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
CA2771472A1 (en) 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
WO2011140425A1 (en) 2010-05-06 2011-11-10 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
JP2014500303A (ja) 2010-12-22 2014-01-09 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としての置換ピリジン
CA2825204C (en) 2011-02-02 2019-06-11 Vertex Pharmaceuticals Incorporated Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
WO2012112743A1 (en) 2011-02-18 2012-08-23 Vertex Pharmaceuticals Incorporated Chroman - spirocyclic piperidine amides as modulators of ion channels
EP3009427B1 (en) 2011-03-03 2019-12-18 Zalicus Pharmaceuticals Ltd. Benzimidazole inhibitors of the sodium channel
CN103517910B (zh) 2011-03-14 2016-12-14 沃泰克斯药物股份有限公司 作为离子通道调节剂的吗啉-螺环哌啶酰胺
TWI567061B (zh) * 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
WO2013012104A1 (ko) 2011-07-18 2013-01-24 엘지전자 주식회사 전자기기 및 전자기기의 동작 방법
PT2753606T (pt) * 2011-09-02 2017-10-02 Purdue Pharma Lp Pirimidinas como bloqueadoras dos canais de sódio
EA023375B1 (ru) 2011-10-26 2016-05-31 Пфайзер Лимитед Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов
WO2013109521A1 (en) 2012-01-16 2013-07-25 Vertex Pharmaceuticals Incorporated Pyran-spirocyclic piperidine amides as modulators of ion channels
ES2548228T3 (es) 2012-02-03 2015-10-15 Pfizer Inc Derivados de bencimidazol e imidazopiridina como moduladores de canal de sodio
WO2013130625A1 (en) * 2012-02-27 2013-09-06 Basil Rigas Phospho-ester derivatives and uses thereof
WO2013131018A1 (en) 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
MD4590C1 (ro) 2012-03-06 2019-03-31 Pfizer Inc. Derivaţi macrociclici pentru tratamentul bolilor proliferative
NZ750187A (en) 2013-01-31 2020-09-25 Vertex Pharma Pyridone amides as modulators of sodium channels
AU2014212426B8 (en) 2013-01-31 2018-05-10 Vertex Pharmaceuticals Incorporated Quinoline and Quinoxaline Amides as Modulators of Sodium Channels
SG11201505954RA (en) 2013-01-31 2015-08-28 Vertex Pharma Amides as modulators of sodium channels
TWI606048B (zh) 2013-01-31 2017-11-21 帝人製藥股份有限公司 唑苯衍生物
KR102215620B1 (ko) 2013-07-19 2021-02-16 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 설폰아미드
EP3459958A1 (en) 2013-12-13 2019-03-27 Vertex Pharmaceuticals Incorporated Process and intermediates for preparing prodrugs of pyridone amides useful as modulators of sodium channels
PE20201164A1 (es) 2017-07-11 2020-10-28 Vertex Pharma Carboxamidas como moduladores de los canales de sodio
AU2019218387A1 (en) 2018-02-12 2020-08-27 Vertex Pharmaceuticals Incorporated A method of treating pain

Also Published As

Publication number Publication date
PT3080134T (pt) 2018-11-08
CN108395452B (zh) 2021-08-03
US9828397B2 (en) 2017-11-28
LT3080134T (lt) 2018-11-12
RS57700B1 (sr) 2018-12-31
US20200377535A1 (en) 2020-12-03
HRP20181563T1 (hr) 2018-11-30
GEP20207082B (en) 2020-04-10
TW202014425A (zh) 2020-04-16
AU2014362255B2 (en) 2019-08-29
NZ760006A (en) 2022-07-29
PE20161131A1 (es) 2016-10-29
BR122020007729B1 (pt) 2023-05-09
TWI703154B (zh) 2020-09-01
US9464102B2 (en) 2016-10-11
ZA201603546B (en) 2023-12-20
SG10201913313QA (en) 2020-03-30
US10253054B2 (en) 2019-04-09
IL246061A0 (en) 2016-07-31
CA2931550A1 (en) 2015-06-18
JP2019055974A (ja) 2019-04-11
TWI651329B (zh) 2019-02-21
PL3080134T3 (pl) 2019-01-31
US20180044361A1 (en) 2018-02-15
SI3080134T1 (sl) 2018-11-30
US20150166589A1 (en) 2015-06-18
CN105814067B (zh) 2018-05-18
ECSP16025201A (es) 2017-02-24
GEP20217223B (en) 2021-02-10
US10787472B2 (en) 2020-09-29
UA121379C2 (uk) 2020-05-25
CA2931550C (en) 2023-09-26
TW201609779A (zh) 2016-03-16
EP3080134B1 (en) 2018-08-01
JP6463580B2 (ja) 2019-02-06
KR20160098380A (ko) 2016-08-18
WO2015089361A1 (en) 2015-06-18
US20160376295A1 (en) 2016-12-29
JP2017504591A (ja) 2017-02-09
IL246061B (en) 2021-12-01
KR102435145B1 (ko) 2022-08-24
US20190276483A1 (en) 2019-09-12
ES2688590T3 (es) 2018-11-05
EP3459958A1 (en) 2019-03-27
NZ720444A (en) 2022-07-29
AU2014362255A1 (en) 2016-06-09
PH12016501028A1 (en) 2016-07-04
US9163042B2 (en) 2015-10-20
US20160009743A1 (en) 2016-01-14
CN108395452A (zh) 2018-08-14
AU2019271928B2 (en) 2021-04-22
JP7465174B2 (ja) 2024-04-10
SG11201604477SA (en) 2016-07-28
GEAP201914203A (es) 2019-11-25
US11773119B2 (en) 2023-10-03
MX2016007258A (es) 2016-08-04
DK3080134T3 (en) 2018-10-22
TW201920221A (zh) 2019-06-01
AU2019271928A1 (en) 2019-12-19
EP3080134A1 (en) 2016-10-19
CY1121030T1 (el) 2019-12-11
RU2019117783A (ru) 2020-02-20
TWI668226B (zh) 2019-08-11
MX2021000781A (es) 2021-04-28
RU2692766C1 (ru) 2019-06-27
JP2020189862A (ja) 2020-11-26
CN105814067A (zh) 2016-07-27
AP2016009287A0 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
CL2016001400A1 (es) Profármacos de amidas de piridona útiles como moduladores de canales de sodio.
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
PH12016500777A1 (en) Compositions and methods for modulating farnesoid x receptors
CL2015002147A1 (es) Amidas piridona como modulares de los canales de sodio
PH12018500777A1 (en) Farnesoid x receptor modulators
CL2017001050A1 (es) Nuevos compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
UY34062A (es) ?compuestos heterocíclicos fusionados moduladores de canal ionico para el tratamiento de enfermedades que responden al bloqueo de canal de sodio?.
ECSP16005566A (es) Sulfonamidas como moduladores de canales de sodio
PH12015501740A1 (en) Sodium channel modulators for the treatment of pain
PH12015501996B1 (en) Heterocyclic compounds and uses thereof
MX367420B (es) Metodos y composiciones para inhibicion de proteinas que contienen bromodominio.
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
NZ710111A (en) Quinoline and quinoxaline amides as modulators of sodium channels
JO3466B1 (ar) مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
TN2015000519A1 (en) Small molecule inhibitors of fibrosis
MX2016004540A (es) Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
PH12015502032A1 (en) Azetidinyloxyphenylpyrrolidine compounds
MX2016002043A (es) Imidazoles sustituidos como bloqueadores de canales de calcio tipo n.
UA89428U (en) 2-(14,15-dioxa-7-azadispirro[5,1,5,2]pentadec -7-yl)ethanol